Depression and Anxiety Trial, Recruiting NCT05925322 Sponsor: Weill Medical College of Cornell University Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT05925322
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between the ages of 50 and 80 (the trial aims for roughly half of participants to be older than 65)
  • People who have reported having thoughts of suicide, as measured by a specific structured interview tool (confirm with trial site for exact scoring details)
  • People who have been diagnosed with Major Depressive Disorder using a standardised clinical interview
  • People whose depression scores 16 or higher on a recognised depression rating scale called the MADRS
  • People who score 23 or higher on a standard memory and thinking test called the Mini Mental Status Exam
  • People who are either not taking antidepressants, or who have been on a stable antidepressant dose for at least 8 weeks and do not plan to change that dose during the study period, and who are not currently receiving one-on-one talk therapy
  • People who have the ability to understand and agree to research assessments and treatment

Who may not be able to join:

  • People who currently have a plan or intention to attempt suicide in the near future
  • People who have, or have had, a psychiatric diagnosis other than Major Depressive Disorder (without psychotic features), generalised anxiety disorder, or a specific phobia
  • People taking psychiatric medications or cholinesterase inhibitor drugs, except for those taking 0.5 mg or less of lorazepam per day (up to seven times per week)
  • People with neurological conditions such as dementia, Parkinson's disease, epilepsy, or certain types of mild cognitive impairment
  • People who have had a serious medical illness in the past 3 months — such as a stroke, heart attack, major surgery, organ failure, metastatic cancer, or similar conditions — that could be contributing to depression, affecting the brain, or making study participation difficult
  • People who cannot safely have an MRI scan, including those with a pacemaker, heart valve replacement, vascular stent, insulin pump, cochlear implant, other metal implants in the body, or those who experience claustrophobia (fear of enclosed spaces)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Nili Solomonov, PhD, Weill Medical College of Cornell University

Phone: (914) 682-9100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
18 September 2023
Est. completion
30 September 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in resting state functional connectivity of the Positive Valence System; Change in STAR task reaction time following social feedback

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov